Compare SNFCA & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SNFCA | ACOG |
|---|---|---|
| Founded | 1965 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.2M | 193.6M |
| IPO Year | 1995 | 2024 |
| Metric | SNFCA | ACOG |
|---|---|---|
| Price | $8.79 | $8.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 24.7K | ★ 162.7K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.51 | ★ 41.58 |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $344,587,538.00 | $10,220,275.00 |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | $14.48 | ★ N/A |
| Revenue Growth | ★ 3.01 | N/A |
| 52 Week Low | $7.70 | $4.50 |
| 52 Week High | $10.23 | $10.14 |
| Indicator | SNFCA | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 47.57 |
| Support Level | $8.53 | $5.28 |
| Resistance Level | $9.40 | $9.04 |
| Average True Range (ATR) | 0.21 | 0.55 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 11.49 | 3.91 |
Security National Financial Corp is a holding company providing insurance services. The company operates in three reportable business segments: Life insurance, Cemetery and Mortuary, and Mortgages. The life insurance segment sells and services selected lines of life insurance, annuity products, and accident and health insurance. The cemetery and mortuary segment engages in pre-need selling of funeral, cemetery, mortuary, and cremation services through its cemetery and mortuary locations. The mortgage segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and other real estate projects. It derives the majority of revenue from Life Insurance segment.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.